HANGZHOU, China, SHANGHAI and BOSTON, July 8, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced that the first patient was successfully dosed on...
Hence then, the article about lynk pharmaceuticals announces first patient dosed in phase ii clinical trial of lnk01004 ointment for vitiligo was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial of LNK01004 Ointment for Vitiligo )
Also on site :
- Emmys 2026: ‘Widow’s Bay’ Leads All New Shows With 19 Nominations
- ‘Elize: Shadows Of A Woman’ Trailer: Netflix Brazil Feature Based On Case Explored In ‘Elize Matsunaga: Once Upon a Crime’
- Dem Sen. Mark Kelly's Warning About How Trump Might Try to 'Intimidate Voters' Is Backfiring Hard